TMTC4

Across TCGA pan-cancer cohorts, TMTC4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMTC4 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TMTC4 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated TMTC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and LUSC are the cancer types where TMTC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.860	.004	34	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	30	view →
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	28	view →
BRCA	OS	Median	III,IV	0.198	0.833	<.001	12	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
GBM	DFS	Median	All	0.048	0.257	.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMTC4–UCEC (OS)

Open the UCEC breakdown →